2024 Latest News for RP - InGel’s Cell Therapy

InGel Therapeutics is developing an innovative cellular treatment aimed at preserving cone-mediated vision in people with retinitis pigmentosa (RP), Usher syndrome, and potentially other retinal conditions, regardless of the specific gene mutations involved.
InGel’s therapy utilizes purified rod photoreceptor precursors-immature rods-that secrete exosomes. These vesicles contain up to 550 protective molecules, which naturally penetrate the patients’ existing cone photoreceptors.
These rod precursors are embedded in a biodegradable hydrogel, a material that mimics the vitreous humor of the eye. This hydrogel protects the precursors from stress damage during injection into the vitreous cavity of the patient’s eye via a syringe.
InGel’s approach is considered potentially more effective than ReNeuron’s for three key reasons: 1) InGel’s cells are purer and deliver a higher quantity of cone-preserving molecules, 2) the protective hydrogel results in a greater yield of healthy, therapeutic cells, and 3) intravitreal delivery allows for the safer administration of more cells compared to subretinal delivery.
Currently, InGel’s cell therapy is being evaluated in large animal studies, with efficacy already observed in mice with RP. For the latest updates on RP treatment, please subscribe to our CZcams channel or newsletter. We will keep you informed.
----------------------------------------------------------------------------------------------------------------------
For more information and online order of AC STIM:
www.restorevis...
For information about V20 Light, please check:
www.restorevis...
For more information and online order of StemActiv :
www.restorevis...
For more information about OCU-ION:
www.restorevis...
Contact us for any question about restore vision:
[e-mail]

[@sanasayed6505]

good information

[@datogunashvili6569]

retina?